GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eutilex Co Ltd (XKRX:263050) » Definitions » EV-to-FCF

Eutilex Co (XKRX:263050) EV-to-FCF : -2.44 (As of Jun. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eutilex Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eutilex Co's Enterprise Value is ₩59,142.1 Mil. Eutilex Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-24,236.0 Mil. Therefore, Eutilex Co's EV-to-FCF for today is -2.44.

The historical rank and industry rank for Eutilex Co's EV-to-FCF or its related term are showing as below:

XKRX:263050' s EV-to-FCF Range Over the Past 10 Years
Min: -59.37   Med: -11.95   Max: -2.01
Current: -2.45

During the past 9 years, the highest EV-to-FCF of Eutilex Co was -2.01. The lowest was -59.37. And the median was -11.95.

XKRX:263050's EV-to-FCF is ranked worse than
100% of 382 companies
in the Biotechnology industry
Industry Median: 8.405 vs XKRX:263050: -2.45

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Eutilex Co's stock price is ₩2100.00. Eutilex Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-724.000. Therefore, Eutilex Co's PE Ratio for today is At Loss.


Eutilex Co EV-to-FCF Historical Data

The historical data trend for Eutilex Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eutilex Co EV-to-FCF Chart

Eutilex Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -17.28 -22.17 -9.42 -5.92 -3.66

Eutilex Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.58 -3.64 -2.85 -3.66 -3.46

Competitive Comparison of Eutilex Co's EV-to-FCF

For the Biotechnology subindustry, Eutilex Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eutilex Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eutilex Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Eutilex Co's EV-to-FCF falls into.



Eutilex Co EV-to-FCF Calculation

Eutilex Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=59142.119/-24236.047
=-2.44

Eutilex Co's current Enterprise Value is ₩59,142.1 Mil.
Eutilex Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-24,236.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eutilex Co  (XKRX:263050) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Eutilex Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2100.00/-724.000
=At Loss

Eutilex Co's share price for today is ₩2100.00.
Eutilex Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-724.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Eutilex Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Eutilex Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eutilex Co (XKRX:263050) Business Description

Traded in Other Exchanges
N/A
Address
Daeryung Technotown 17, Suite 1401, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, KOR, 08594
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.

Eutilex Co (XKRX:263050) Headlines

No Headlines